ACTRN12621000611820招募中2 期
Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction
St Vincent's Hospital, Sydney0 个研究点目标入组 22 人开始时间: 2021年5月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Male
入选标准
- •1. Male, aged 18 years or older
- •2. Pathologically confirmed adenocarcinoma of prostate or a clinical presentation consistent with prostate cancer
- •3. Metastatic castrate resistant prostate cancer previously confirmed on 68Ga-PSMA-11 and 18F-FDG imaging to be inadequate for future PSMA-directed theranostic treatment by a nuclear medicine physician based on FDG-discordance (FDG-positive, PSMA-negative sites of disease) OR low PSMA SUV values within 2 weeks of starting study drug
- •4. Adequate hematologic and organ function within 14 days before the first study treatment
- •5. Castrate levels of testosterone < 1.7 ng/ml
- •6. Provision of written informed consent.
排除标准
- •1. Patients who cannot lie still for at least 30 minutes or comply with imaging.
- •2. Previous dasatinib for prostate cancer or other condition, eg CLL
- •3. Allergy to dasatinib or darolutamide
- •4. Use of drugs that interact with interact pharmacologically with dasatinib within 1 week of study entry eg Use of CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or St John’s Wort) and use of CYP3A4 substrates with narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot analogues.
- •5. Use Concomitant use of H2 antagonists or proton pump inhibitors.
- •6. Current or previous (within the last 6 months) pleural effusion
- •7. Use of paracetamol during the study period
- •8. Subjects may not have any of the following: Clinical evidence of uncontrolled heart failure, myocardial infarction, or angina within the previous 6 months; prolonged QT interval Fridericia's (QTcF) > 450msec; history of unstable ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation, or torsades de pointes); concomitant use of drugs known to cause torsades de pointes [quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins, clarithromycin, chlorpromazine, haloperidol, mesoridazine,thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl,pentamidine, sparfloxacin, lidoflazine] (these agents must have been discontinued at least 7 days prior to starting dasatinib)
- •9. Subjects may not be enrolled with any of the following: History of a significant bleeding disorder unrelated to cancer, including diagnosed congenital bleeding disorders (e.g., von Willebrand's disease), and diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies); GI bleeding from any cause within 3 months
研究者
相似试验
尚未招募
不适用
Prostate-specific Membrane Antigen (PSMA) expression in cervical carcinomaC53.9Cervix uteri, unspecifiedDRKS00023289niversitätsklinikum FreiburgKlinik für Frauenheilkunde100
已完成
不适用
Prostate-specific Membrane Antigen (PSMA) expression in endometrial cancerC54Malignant neoplasm of corpus uteriDRKS00025005niversitätsklinikum Freiburg Klinik für Frauenheilkunde61
尚未招募
不适用
Prostate-specific membrane antigen (PSMA) expression in ovarian carcinomaC56Malignant neoplasm of ovaryDRKS00023240niversitätsklinikum Freiburg Klinik für Frauenheilkunde100
招募中
2 期
Expression of prostate specific membrane antigen (PSMA) in soft tissue sarcomas and urothelial cell carcinomas: implications for tumour-specific molecular imaging and treatment?cohort 1: soft tissue cancercohort 2: transitional cell carcinomasoft tissue tumour1002838910004994bladder cancerNL-OMON54064eids Universitair Medisch Centrum120
尚未招募
1 期
Emerging digital imaging-guided theranostic therapy for newly diagnosed high risk prostate cancer patients: A feasibility studyCancer - ProstateProstate CancerACTRN12620001358932I-MED Radiology Network5